Literature DB >> 15665884

[Buprenorphine and methadone to opiate addicts--a randomized trial].

Øistein Kristensen1, Olav Espegren, Reidun Asland, Else Jakobsen, Øystein Lie, Stephen Seiler.   

Abstract

BACKGROUND: There are approximately 12,000 opioid dependants in Norway. Methadone-assisted treatment was approved in Norway in 1998, buprenorphine in 2000. This study compares the efficacy of methadone (n = 25) and buprenorphine (n = 25) assisted maintenance treatment in a group of long-term (> 10 years) opioid dependant.
MATERIAL AND METHODS: After randomisation patients received either 16 mg sublingual buprenorphine or individually adjusted methadone (mean 106 mg, range 80 - 160) for 26 weeks, with a rehabilitation programme run in parallel.
RESULTS: After 180 days, patient retention was highest in the methadone group (85 % vs. 36 %, p < 0.0005). Days in treatment were 167 vs. 114 (95 % CI for difference 53 days (26-80), p < 0.001). Positive urine test rates for opiates (20 % vs 24 %, p < 0.01) and cannabis (33 % vs 45 %, p < 0.001) were lower in the methadone group which also had lower self-reported risk behaviour and psychological distress. However, only those on buprenorphine reported significant improvement in physical health. For older, long-term opioid dependants with significant co-morbidity and unsuccessful medication-free treatment, high-dose methadone maintenance appears to be the treatment of choice. However, in cases where methadone is poorly tolerated, buprenorphine therapy may be a good alternative.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15665884

Source DB:  PubMed          Journal:  Tidsskr Nor Laegeforen        ISSN: 0029-2001


  6 in total

1.  Patient perspectives on buprenorphine/naloxone: a qualitative study of retention during the starting treatment with agonist replacement therapies (START) study.

Authors:  Cheryl Teruya; Robert P Schwartz; Shannon Gwin Mitchell; Albert L Hasson; Christie Thomas; Samantha H Buoncristiani; Yih-Ing Hser; Katharina Wiest; Allan J Cohen; Naomi Glick; Petra Jacobs; Paul McLaughlin; Walter Ling
Journal:  J Psychoactive Drugs       Date:  2014 Nov-Dec

Review 2.  Opioid agonist treatment for people who are dependent on pharmaceutical opioids.

Authors:  Suzanne Nielsen; Wai Chung Tse; Briony Larance
Journal:  Cochrane Database Syst Rev       Date:  2022-09-05

Review 3.  Methadone at tapered doses for the management of opioid withdrawal.

Authors:  Laura Amato; Marina Davoli; Silvia Minozzi; Eliana Ferroni; Robert Ali; Marica Ferri
Journal:  Cochrane Database Syst Rev       Date:  2013-02-28

4.  Relative effectiveness of medications for opioid-related disorders: A systematic review and network meta-analysis of randomized controlled trials.

Authors:  Jihoon Lim; Imen Farhat; Antonios Douros; Dimitra Panagiotoglou
Journal:  PLoS One       Date:  2022-03-31       Impact factor: 3.240

5.  Comparative effectiveness of buprenorphine-naloxone versus methadone for treatment of opioid use disorder: a population-based observational study protocol in British Columbia, Canada.

Authors:  Micah Piske; Trevor Thomson; Emanuel Krebs; Natt Hongdilokkul; Julie Bruneau; Sander Greenland; Paul Gustafson; M Ehsan Karim; Lawrence C McCandless; Malcolm Maclure; Robert W Platt; Uwe Siebert; M Eugenia Socías; Judith I Tsui; Evan Wood; Bohdan Nosyk
Journal:  BMJ Open       Date:  2020-09-09       Impact factor: 2.692

6.  Evaluation of buprenorphine/naloxone dose and use of sedating supportive medication on treatment outcomes in veterans with opioid use disorder.

Authors:  Amber Kapuganti; Traci Turner; Christopher J Thomas
Journal:  Ment Health Clin       Date:  2018-03-23
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.